Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
FDMT - 4D Molecular Therapeutics, Inc.
Market Cap 738.02M P/E - EPS this Y -8.50% Ern Qtrly Grth -
Income -109.89M Forward P/E -5.13 EPS next Y -17.50% 50D Avg Chg 2.00%
Sales 20.22M PEG 0.25 EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 2.52 EPS next 5Y -15.90% 52W High Chg -32.00%
Recommedations 1.80 Quick Ratio 27.93 Shares Outstanding 51.97M 52W Low Chg 236.00%
Insider Own 3.48% ROA -16.86% Shares Float 26.40M Beta 2.79
Inst Own 112.50% ROE -24.06% Shares Shorted/Prior 9.52M/9.95M Price 17.89
Gross Margin - Profit Margin - Avg. Volume 551,431 Target Price 50.00
Oper. Margin -849,120.00% Earnings Date Nov 7 Volume 396,220 Change 0.39%
Healthcare | Biotechnology | United States
About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc. News
12/16/24 4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
11/26/24 4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now
11/14/24 4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
11/13/24 4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
11/13/24 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
10/30/24 We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
10/14/24 Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
09/25/24 4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
09/23/24 4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
09/19/24 4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
09/19/24 4D Molecular data ‘bode well’ for eye gene therapy, but shares fall
09/18/24 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
09/05/24 4DMT Announces Presentations at Upcoming Retina Conferences
09/03/24 4DMT to Participate in the 2024 Cantor Global Healthcare Conference
08/27/24 4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
08/23/24 4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
08/12/24 4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
08/10/24 4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
08/08/24 4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
08/08/24 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kirn David Chief Executive Offi.. Chief Executive Officer Jan 23 Sell 18.4079 5,696 104,851 1,151,154 01/25/24
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jan 04 Sell 19.53 540,000 10,546,200 4,247,914 01/05/24
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 08 Sell 20.85 3,750 78,188 1,737 06/12/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 08 Option 8.04 3,750 30,150 5,487 06/12/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 01 Sell 18.31 2,247 41,143 1,737 06/06/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 01 Option 6.49 1,875 12,169 3,984 06/06/23
Moretti August J Chief Financial Offi.. Chief Financial Officer May 15 Option 9.41 3,000 28,230 11,045 05/16/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Apr 21 Sell 20 3,750 75,000 2,109 04/25/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Apr 21 Option 8.04 3,750 30,150 5,859 04/25/23
Chacko Jacob Director Director Apr 21 Sell 20.05 5,000 100,250 04/25/23
Chacko Jacob Director Director Apr 21 Option 9.41 5,000 47,050 5,000 04/25/23
Kirn David Chief Executive Offi.. Chief Executive Officer Feb 21 Sell 20.88 34,446 719,232 1,859,153 02/23/23
Kirn David Chief Executive Offi.. Chief Executive Officer Jan 19 Sell 20.11 19,524 392,628 1,893,599 01/23/23
Moretti August J Chief Financial Offi.. Chief Financial Officer Dec 21 Option 9.41 3,000 28,230 6,595 12/22/22
Kirn David Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 23.44 86,877 2,036,397 1,913,123 12/19/22
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Dec 01 Option 7.27 5,625 40,894 6,607 12/05/22
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Dec 01 Sell 23.22 6,000 139,320 2,482 12/05/22
SCHAFFER DAVID Director Director Oct 20 Sell 31.19 36,285 1,131,729 901,215 10/22/21